A Bloomberg survey found industry players predict Humira biosimilar copies will be most successful when launched in the EU and U.S.
According to a Bloomberg Intelligence survey, biosimilar copies of AbbVie’s top-earning autoimmune anti-inflammatory drug, Humira, are expected to be the most successful biosimilars to be launched in the U.S. and Europe in the coming year.
The respondents saw Humira’s $12.5 billion revenue (2014), and the $14 billion it’s expected to generate in 2015, as an attractive opportunity for biosimilar manufacturers.
The majority of respondents thought only 20 to 40 per cent of biosimilar drugs seeking interchangeability approval will succeed. Over 33.33 per cent of respondents seemed optimistic, predicting that over 40 per cent of the biosimilars will successfully gain interchangeability. But a FiercePharma article says industry-watchers predict the drugs could face initial skepticism from doctors and patients.
